IN VITRO STUDIES: XLEAR KILLS AND/OR DEACTIVATES SARS-COV-2

30 NOV 2020

KUALA LUMPUR: New in vitro studies led by renowned authority on respiratory diseases conclude that Xlear nasal spray is “an effective...and replicable means to deactivate SARS-CoV-2...to an undetectable amount of infectious virus.”

This is “validated by two independent sets of experiments, performed by different labs, on different viral strains...” The Virucidal studies were independently funded.

“The Virucidal Studies shed important light on the role Xlear can play in helping combat the COVID-19 pandemic,” said research team leader, Dr Gustavo Ferrer.

Nasal sprays, such as Xlear, reduce viral load in the nose, which is vital in fighting COVID-19, according to a statement.

Research shows COVID-19 primarily infects and spreads through the upper respiratory system. By reducing viral load in the nose, nasal sprays help limit the severity and transmission of SARS-CoV-2 (COVID-19).

Xlear has been used for over 20 years by millions of people worldwide without a single significant adverse incident report. “Building on the existing data, these Virucidal Studies show Xlear is not just antiviral, it is virucidal (kills/deactivates SARS-CoV-2). This combination of antiviral and virucidal capabilities is an important one-two punch in fighting the virus,” said Xlear Chief Executive Officer, Nathan Jones.

For details, visit https://xlear.com/ - Bernama